SEC Receives Amended Filing for 21Shares Injective ETF
The Securities and Exchange Commission (SEC) has received an amended registration statement for the 21Shares Injective ETF, moving it one step closer to potentially becoming a publicly traded product. The proposed fund would give traditional investors regulated access to INJ, the native token of the Injective Network.
If approved, the ETF would list on Nasdaq under the ticker TINJ and track the performance of the FTSE Injective Index with an added twist: discretionary staking of a portion of holdings to boost returns. The fund plans to stake a portion of its INJ holdings at its discretion, a strategy designed to optimize performance while staying within regulatory guardrails.
As of September 1, 2026, the circulating supply of INJ stood at approximately 92.8 million tokens, with a market capitalization near $488 million. This has raised eyebrows in the crypto space, as some investors see the potential for an altcoin ETF to attract significant assets.